Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 in chronic hepatitis B
NCT02349126Phase 2Withdrawn
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARC-520 in Chronic Hepatitis B (CHB), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Hepatitis B surface antigen decline at 12 weeks. Planned start Feb 2015; status: withdrawn.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02349126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349126.